Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085483 | 0.89 | ACLY (0.38) | ACLY | |
| SCHEMBL9423113 | 0.87 | ACLY (0.38) | ACLYALDH1A1GAA | |
| SCHEMBL7081981 | 0.84 | ACLY (0.36) | ACLYALDH1A1GAACA2 | |
| SCHEMBL7085267 | 0.82 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL7080892 | 0.80 | LMNA (0.38) | — | |
| SCHEMBL7081976 | 0.80 | RBP4 (0.39) | CA2NPSR1 | |
| SCHEMBL7082216 | 0.79 | DUT (0.34) | ACLYALDH1A1GAA | |
| SCHEMBL7085484 | 0.76 | ACLY (0.36) | ACLY | |
| SCHEMBL7080977 | 0.74 | — | — | |
| SCHEMBL9139069 | 0.74 | CA2 (0.38) | ALDH1A1CA2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0592439-B1 | AMINOSULFONYL CARBAMATES | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | HOMAN REYNOLD (US) | 2003-07-17 | — | — | US | claimed |
| EP-1281399-A2 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | WARNER-LAMBERT COMPANY (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| US-5336690-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1994-08-09 | — | — | US | claimed |
| EP-0592439-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1992008693-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | claimed |
| EP-0592439-B1 | AMINOSULFONYL CARBAMATES | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | HOMAN REYNOLD (US) | 2003-07-17 | — | — | US | disclosed |
| EP-1281399-A2 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | WARNER-LAMBERT COMPANY (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5336690-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1994-08-09 | — | — | US | disclosed |
| US-5254715-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | ACLY 1020/4885ALDH1A1 4328/4885GAA 2267/4885 |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | ACAT2, LCAT, SOAT1 | ACLY 282/4885ALDH1A1 412/4885GAA 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.